Author

M. A. Nix

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:deep learning· 2

Frequent Co-Authors

A. P. Wiita· 5 shared B. P. Escobar· 2 shared E. Ramos· 2 shared I. D. Ferguson· 2 shared J. A. Wells· 2 shared K. K. Leung· 2 shared A. D. Leavitt· 1 shared A. Glasgow· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target

K. Mandal, G. Wicaksono, C. Yu, J. J. Adams, M. R. Hoopmann, W. C. Temple, B. P. Escobar, M. Gorelik, C. H. Ihling, M. A. Nix, A. Naik, E. Ramos, C. Kasap, V. Steri, J. A. C. Serrano, , A. P. Wiita

The paper identifies an AML-specific conformation of Integrin-β2 using structural surfaceomics and demonstrates its targeting by CAR-T cells.

bioRxiv · Oct 10, 2022 · PreprintCancer Biology

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

I. D. Ferguson, B. P. Escobar, S. T. Tuomivaara, Y.-H. T. Lin, M. A. Nix, K. K. Leung, M. Hale, P. Choudhry, A. Lopez-Girona, E. Ramos, S. W. Wong, J. L. Wolf, T. G. Martin, N. Shah, S. Vandenberg, , A. P. Wiita

This study defines the myeloma cell surface proteome, identifies therapeutic targets and resistance biomarkers, and presents a miniaturized surface proteomics protocol.

bioRxiv · Jan 17, 2021Cancer Biology

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

A. Glasgow, J. E. Glasgow, D. Limonta, P. Solomon, I. Lui, Y. Zhang, M. A. Nix, N. J. Rettko, S. A. Lim, S. Zha, R. Yamin, K. Kao, O. S. Rosenberg, J. V. Ravetch, A. P. Wiita, , J. A. Wells

This paper describes engineered ACE2 receptor traps that potently neutralize SARS-CoV-2 by blocking viral entry through enhanced binding affinity.

bioRxiv · Jul 31, 2020Bioengineering

Signaling input from divergent pathways subverts malignant B-cell transformation

L. N. Chan, M. A. Murakami, M. E. Robinson, R. Caeser, T. Sadras, J. Lee, K. N. Cosgun, K. Kume, V. Khairnar, G. Xiao, M. Ahmed, E. Aghania, G. Deb, C. Hurtz, S. Shojaee, , M. Muschen

This study shows that malignant B-cell transformation requires convergence on a single oncogenic pathway, while divergent pathways can subvert transformation and are targets for new therapeutic strategies.

bioRxiv · Mar 12, 2020Cancer Biology

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis

V. Sarin, K. Yu, I. D. Ferguson, O. Gugliemini, M. A. Nix, B. C. Hann, M. Sirota, A. P. Wiita

This study evaluates how well multiple myeloma cell lines represent patient tumors using transcriptomic correlation analysis, finding significant variation in their similarity to patient tumors.

bioRxiv · Nov 20, 2019Cancer Biology